BTK and COVID-19: In a preliminary, non-controlled clinical study of 19 patients hospitalized with severe COVID-19, off-label use of the selective BTK inhibitor acalabrutinib improved oxygenation in the majority of patients, often within 1 to 3 d, with no discernible toxicity.8